Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung

NCT ID: NCT00391586

Last Updated: 2015-08-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-07-31
• Study Completion Date: 2012-05-31

Brief Summary

This study was conducted to compare the activities of erlotinib to that of intravenous, platinum-based therapy in the treatment of non-small cell lung cancer (NSCLC). The goal of this trial was to demonstrate clinical equivalence of erlotinib to platinum-based frontline therapy, compared to historical controls.

Detailed Description

To compare the activities (the progression-free survival, the incidence and severity of toxicities, and reversibility of toxicities) of erlotinib to that of platinum-based therapy in NSCLC. A sequential therapy design has been chosen such that all patients will receive any potential benefits of both platinum-based and erlotinib therapy, without compromising survival by denying anyone potential therapy. With this design, progression-free survival will be tracked by treatment received. However, data will be generated which will show the safety and efficacy of erlotinib in the frontline setting (alone and with historical comparison to platinum-based therapy), as well as the potential safety and activity of platinum-based therapy in the "second-line" (post-erlotinib) setting. This should allow for the demonstration of the relative median time to progression, objective response and clinical benefit rates, overall survival, and safety and tolerability of erlotinib and platinum-based therapy in both the frontline and second-line settings in NSCLC. Also, in this fashion, the treatments serve as controls for each other, as well as being compared to historical controls; in the first line treatment portion, the platinum-based regimens serve as the historical control, while in the second-line setting, erlotinib serves as the historical control arm.

Conditions

Carcinoma, Non-Small-Cell Lung

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Erlotinib followed by chemotherapy

Erlotinib: 150 mg orally once daily,

Platinum-based chemotherapy regimen selections include:

Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:

1. Docetaxel 75 mg/m2, D1

2. Docetaxel 35 mg/m2, D1,8,15

3. Paclitaxel 200-225 mg/m2, D1

4. Paclitaxel 80-100 mg/m2, D1,8,15

Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:

1. Etoposide 100 mg/m2 D1-3

2. Etoposide 200 mg/m2 orally D1-3

3. Pemetrexed 500 mg/m2, D 1

4. Irinotecan 50 mg/m2 D1,8,15

Other regimens:

1. Gemcitabine 1000 mg/m2-1250 mg/m2, D1,8 + Carbo AUC 6, or Cis 60-100 mg/m2, D1 or 8

2. Vinorelbine 25 mg/m2 D1,8 + Carbo AUC 5, or Cis 80 mg/m2 D1

Group Type: EXPERIMENTAL

Erlotinib

Intervention Type: DRUG

Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.

Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient

Platinum-based chemotherapy

Intervention Type: DRUG

Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles

Interventions

Erlotinib

Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.

Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient

Intervention Type: DRUG

Platinum-based chemotherapy

Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles

Intervention Type: DRUG

Other Intervention Names

Tarceva; OSI-774; paclitaxel + platinum; docetaxel + platinum; vinorelbine + platinum; pemetrexed + platinum; irinotecan + platinum; etoposide + platinum; gemcitabine + platinum

Eligibility Criteria

Inclusion Criteria

• Prior chemotherapy will be allowed for other invasive malignancies, provided at least five years has elapsed since the completion of therapy and enrollment on this protocol. No prior chemotherapy for metastatic non-small cell lung cancer (NSCLC) will be allowed. Prior adjuvant or neoadjuvant chemotherapy for NSCLC will be allowed, provided at least six months have elapsed from the last dose of chemotherapy to the documentation of relapsed disease.

Baseline laboratory values (bone marrow, renal, hepatic):

• Adequate bone marrow function:

• Absolute neutrophil count >1000/µL
• Platelet count >100'000/µL
• Renal function:

• Serum creatinine < 2.0 mg %
• Hepatic function:

• Bilirubin <1.5x normal
• Serum calcium < 12 mg/dl

Other Eligibility Criteria:

• Signed Informed Consent
• Eastern Cooperative Oncology Group (ECOG)/Zubrod/Southwest Oncology Group (SWOG) Performance Status <2 (Karnofsky Performance Status > 70%)
• Life expectancy > 8 weeks
• Male or female' age >18 years
• Patients of childbearing potential must be using an effective means of contraception.
• Histologic diagnosis of NSCLC that is advanced and cannot be treated adequately by radiotherapy or surgery; or metastatic disease

Exclusion Criteria

• Prior therapy with an epidermal growth factor receptor inhibitor, including erlotinib, gefitinib, and cetuximab, as well as any investigational HER-1 inhibiting agent
• Pregnant or lactating females
• Myocardial infarction or ischemia within the 6 months before Cycle 0' Day 0
• Uncontrolled' clinically significant dysrhythmia
• History of prior malignancy within the prior five years, with the exception of non-melanoma carcinomas of the skin, and carcinoma in situ of the cervix
• Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor growth in that lesion
• Uncontrolled metastatic disease of the central nervous system (previously treated, stable disease is allowable on this protocol)
• Radiotherapy within the 2 weeks before Cycle 1' Day 1
• Surgery within the 2 weeks before Cycle 1' Day 1
• Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

New Mexico Cancer Research Alliance

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dennie V Jones, MD

Role: PRINCIPAL_INVESTIGATOR

University of New Mexico

Locations

Lovelace Medical Group

Albuquerque, New Mexico, United States

Hematology Oncology Associates NM

Albuquerque, New Mexico, United States

Presbyterian Medical Group

Albuquerque, New Mexico, United States

University of New Mexico Cancer Center

Albuquerque, New Mexico, United States

New Mexico Cancer Care Associates

Santa Fe, New Mexico, United States

Countries

United States

Related Links

http://cancer.unm.edu

UNM CRTC Homepage

Other Identifiers

NCI-2012-01264

Identifier Type: REGISTRY

Identifier Source: secondary_id

INST 0601C

Identifier Type: -

Identifier Source: org_study_id